Israeli Patent Guide

This skill covers the end-to-end patent process in Israel as administered by the Israeli Patent Office (ILPO, also known as Rashut HaPatenTim - רשות הפטנטים). It is scoped to:

• National patent application filing under the Israeli Patents Law, 5727-1967
• Prior art search using ILPO's public database and international resources
• PCT international filing routed through ILPO as Receiving Office
• Official fee schedule, the 40% reduction for qualifying applicants, and maintenance fee structure
• Patent Term Extension (PTE) for pharmaceutical products under Israeli law
• Key deadlines, objection windows, and IDS (Information Disclosure Statement) obligations unique to Israeli practice

This skill does NOT cover trademark registration, industrial design registration, copyright, or utility model protection. It does not replace a licensed Israeli patent attorney for prosecution decisions.

• Novelty check: Before investing in a full application, search ILPO's database and WIPO PatentScope to assess whether an invention is likely new.
• Filing guidance: Step-by-step walkthrough of requirements for filing a national patent application in Israel.
• PCT national phase entry: Understanding timelines and requirements for entering the Israeli national phase from a PCT application.
• Deadline tracking: Calculating maintenance fee due dates, the 30-month PCT window, and the 3-month objection period after allowance.
• PTE calculation: Determining eligibility and maximum extension duration for pharmaceutical patents.
• Fee estimation: Checking whether you qualify for the 40% reduction and estimating total filing and prosecution costs.

Application Requirements

A complete patent application filed with ILPO must include:

1. Request form (Form P/1): applicant name, inventor name(s), title of invention, and claim of priority if applicable.
2. Specification structured as:
   • Description: technical field, background, summary, detailed description of embodiments, and reference to drawings.
   • Claims: numbered, beginning with an independent claim. Claims define the legal scope of protection.
   • Abstract: 150 words or fewer; not part of the legal scope but used for search purposes.
   • Drawings (if applicable): black-and-white line drawings, A4 format, referenced in the description.
3. Priority document: if claiming Convention priority under the Paris Convention, the certified copy must be submitted within 16 months of the priority date (or with the application if filed after 16 months).

Language

Hebrew and English are both accepted as filing languages. If the application is filed in any other language, a Hebrew or English translation must be submitted within 3 months of the filing date. The translation becomes the official text for prosecution purposes.

Address in Israel

Foreign applicants (those without a place of business or domicile in Israel) must appoint a registered Israeli patent attorney or agent as their address for service in Israel. Correspondence from ILPO is sent to this address.

IDS Duty (Section 18, Israeli Patents Law)

Under Section 18 of the Israeli Patents Law, an applicant has a continuing duty to disclose all material prior art known to the applicant throughout prosecution, up to and including the Notice of Acceptance. This duty is substantially broader than USPTO practice:

• The duty applies to all material prior art, including art discovered during foreign prosecution of the same or related applications.
• Failure to disclose material prior art known to the applicant can be raised as a ground for patent revocation, even after grant.
• There is no prescribed form for the IDS in Israel; a letter to the examiner listing the relevant documents is sufficient.
• Best practice: file an IDS when receiving Office Actions or Search Reports from the USPTO, EPO, or any other office examining a counterpart application.

Examination is Automatic

Unlike the USPTO or EPO, Israel does NOT require a separate request for substantive examination. Examination begins automatically once the application is complete and the filing fee is paid. There is no deferred examination system. This is a common point of confusion for applicants and agents trained in US or European practice.

ILPO Database

The ILPO online patent search is available at israelpatents.justice.gov.il. It is free, publicly accessible, and bilingual (Hebrew and English). Key features:

• Full-text search of Israeli patent applications and granted patents
• IPC (International Patent Classification) code filtering
• Applicant/inventor name search
• Status information (pending, granted, lapsed, opposed)

International Databases

Search Strategy

1. IPC classification: Identify the relevant IPC subgroups for your invention. ILPO search supports IPC filtering. Use the IPC classification tool at ipc.inpit.go.jp to find the right codes.
2. Keyword synonyms: Draft a synonym list covering technical terms, trade names, and common alternatives. Run multiple keyword searches; do not rely on a single query.
3. Assignee/inventor search: If you know of competitors or related inventors, search by name in PatentScope and ILPO.
4. Non-patent literature: For biotech and pharma, also search PubMed, journal databases, and conference proceedings. Published scientific papers constitute prior art.
5. Date cutoff: Prior art includes anything publicly available before your priority date, anywhere in the world, in any language.

ILPO as Receiving Office

Israel is a member of the Patent Cooperation Treaty (PCT). ILPO acts as a Receiving Office (RO/IL) for PCT applications filed by Israeli applicants (or applicants with a place of business or residence in Israel). Applications can also be filed directly with WIPO's IB as receiving office.

Filing via ePCT (pct.wipo.int) is strongly recommended over paper filing.

International Searching Authority (ISA) Options

ILPO was recognized as an ISA/IPEA in 2012. Applicants filing through RO/IL can choose:

The choice of ISA affects search quality perception in national phases and the cost of the international phase.

National Phase Entry in Israel

For PCT applications designating Israel, national phase entry must occur within 30 months from the earliest priority date (not the filing date of the PCT application). This is the absolute deadline under Israeli law. Specific steps:

1. File a national phase entry request with ILPO (Form PCT/IL/01 or equivalent).
2. Pay the national phase entry fee.
3. Submit a Hebrew or English translation of the specification if the PCT application was filed in another language.
4. Appoint an Israeli address for service if required.

Fee Payment in NIS

All official ILPO fees are denominated in New Israeli Shekel (NIS). For foreign applicants paying from abroad, fees are converted at the Bank of Israel official exchange rate on the payment date.

40% Fee Reduction

Israel offers a significant fee reduction to qualifying applicants. The 40% reduction applies to:

• Individual inventors (natural persons filing in their own name)
• Companies with annual turnover (revenue) of less than NIS 10 million in the most recent fiscal year

Most early-stage Israeli startups qualify. To claim the reduction, the applicant must submit a declaration of eligibility at the time of filing. The reduction applies to filing fees, examination fees, and most official ILPO fees but does not apply to attorney fees.

Important: The threshold is turnover (revenue), not profit. A company with high revenue but operating at a loss does not qualify if revenue exceeds NIS 10 million.

Fee Structure Overview

Refer to the official ILPO fee schedule at the Ministry of Justice website for current NIS amounts. Key fee categories (approximate, subject to annual CPI adjustment):

See /references/ilpo-fee-schedule.md for a more detailed breakdown.

Maintenance Fee Structure

Patent maintenance (renewal) fees in Israel follow a unique schedule compared to most jurisdictions:

• Years 1 through 6: A lump-sum maintenance fee is paid at the time of grant, covering the first 6 years from the filing date.
• Subsequent years: Annual fees are paid every 4 years in advance, covering years 7-10, 11-14, 15-18, and 19-20.
• Grace period: A 6-month grace period is available for late maintenance payments, subject to a surcharge. After the grace period, the patent lapses.
• Maximum term: 20 years from the filing date (not the priority date).

After ILPO issues a Notice of Acceptance (analogous to a Notice of Allowance), there is a 3-month objection period during which any person may file a formal opposition (objection) to the grant. This period is non-extendable. If an opposition is filed, the patent enters opposition proceedings before ILPO before the patent can be granted. If no opposition is filed within 3 months, the patent is granted.

Overview

Israel provides for Patent Term Extension (PTE) for pharmaceutical products, similar in concept to Supplementary Protection Certificates (SPCs) in the EU. The PTE compensates patentees for time lost during regulatory approval proceedings before the Israeli Ministry of Health.

Filing Window

The application for PTE must be filed with ILPO within 90 days of the date on which the Ministry of Health grants marketing authorization (registration) for the pharmaceutical product in Israel. This 90-day window is non-extendable. Missing it forfeits the right to a PTE entirely.

EU-5 Linkage Requirement

This is a feature unique to Israeli PTE law and is not found in US or standard EU SPC practice. Israeli PTE duration is capped by reference to the shortest patent term extension (or SPC) granted in any of the EU-5 jurisdictions: United Kingdom, Germany, France, Italy, and Spain.

In practice:

• You must obtain SPC or equivalent protection in at least one EU-5 jurisdiction before or concurrent with the Israeli PTE application.
• The Israeli PTE cannot exceed the duration of the shortest EU-5 extension granted for the same product.
• If no EU-5 jurisdiction has granted an extension (e.g., the product was approved only in Israel and not in the EU), the EU-5 linkage requirement effectively prevents PTE in Israel.

Duration Caps

• Maximum PTE duration: 5 years
• Maximum total patent term including PTE: 25 years from the original filing date
• The extension is limited to the shortest EU-5 extension, which may further reduce the available term below 5 years.

1. IDS Duty is Continuous Until Notice of Acceptance

Unlike the USPTO where an IDS is typically filed once at defined stages, Israeli law (Section 18) imposes a continuing duty of disclosure throughout the entire prosecution lifecycle, from filing through the date of Notice of Acceptance. This means that if your US counterpart receives an Office Action citing new art after you filed your Israeli IDS, you must file a supplemental disclosure in Israel. Agents unfamiliar with Israeli practice routinely miss this. Failing to disclose material prior art known to the applicant can result in the patent being held invalid even after grant.

2. Examination is Automatic -- Do Not Wait for a Request

Agents trained on USPTO or EPO procedure often instruct clients to "request examination" or warn about examination deadlines. In Israel, there is no examination request. Substantive examination begins automatically once the application is complete and fees are paid. If an agent or tool tells you to file an "examination request" for an Israeli national application, that instruction is incorrect.

3. The 40% Fee Reduction Threshold is NIS 10M Turnover, Not Profit

Many agents default to quoting full official fees without checking eligibility for the 40% reduction. The threshold is annual turnover (gross revenue) under NIS 10 million. Most early-stage startups qualify. Always verify eligibility at filing; the declaration cannot be added retroactively after fees are paid at full rate.

4. PCT 30-Month Deadline Runs From Priority Date, Not PCT Filing Date

The 30-month national phase entry window in Israel is measured from the earliest priority date claimed in the PCT application. Agents sometimes mistakenly calculate from the international (PCT) filing date, which can differ by up to 12 months from the priority date. A miscalculation here means a missed absolute deadline with no remedy.

5. PTE EU-5 Linkage is Unique to Israel

Attorneys and AI tools trained on US or EU patent law have no frame of reference for the Israeli PTE EU-5 linkage requirement. An agent providing PTE advice without mentioning this requirement is providing incomplete guidance. The practical consequence: if a pharmaceutical product is approved only in Israel without EU-5 SPC protection, PTE in Israel is unavailable, regardless of how long the regulatory approval process took.

Problem: ILPO database search returns no results for a known Israeli patent. Solution: Try searching by publication number directly. The database can lag by 2-4 weeks for new publications. Also check whether the application was filed before the database's coverage start date; older patents may not be fully digitized.

Problem: ILPO rejected a priority document as insufficient. Solution: The priority document must be a certified copy issued by the priority office. Uncertified copies, digital printouts, or WIPO DAS digital access codes may not satisfy ILPO's requirements in all cases. Confirm acceptable formats with an Israeli agent before relying on DAS.

Problem: Applicant is not sure whether they qualify for the 40% fee reduction (company is a subsidiary of a larger group). Solution: ILPO applies the turnover test to the applicant entity as filed, not to a consolidated group. A wholly-owned subsidiary with its own financial statements showing under NIS 10M turnover may qualify even if the parent group is much larger. Verify with a licensed Israeli patent attorney, as this analysis can be fact-specific.

Problem: PCT national phase entry deadline appears to have passed. Solution: Confirm the earliest priority date carefully (it may differ from the PCT filing date). Also confirm whether Israel has ratified Rule 49.6 of the PCT Regulations, which allows reinstatement of the national phase in cases of unintentional failure to meet the deadline. As of the date of this skill, ILPO does accept reinstatement petitions under Rule 49.6, but reinstatement is not guaranteed.

• Israeli Patents Law, 5727-1967 (as amended): Available via the Israeli Ministry of Justice (laws.justice.gov.il)
• ILPO Official Fee Schedule: gov.il/en/departments/ilpo (updated annually; fees are CPI-indexed)
• WIPO PCT Applicant's Guide, Israel Chapter: pctlegal.wipo.int/eGuide/view-doc.xhtml?doc-code=IL
• Patent Cooperation Treaty Regulations, Rule 49.6 (reinstatement)
• Israeli Patents Regulations, 5729-1969
• See also: /references/ilpo-fee-schedule.md, /references/pct-israel-checklist.md

This skill provides informational guidance only. It does not constitute legal advice and does not create an attorney-client relationship. Israeli patent law involves jurisdiction-specific nuances, fact-specific determinations, and professional judgment. For any specific patent matter, consult a licensed Israeli patent attorney registered with the Israeli Patent Office.